Perimenopause Emerging Research and Trials to Watch

HealthRX.com

New non-hormonal hot flash drugs and changing HRT warnings

Print or save as PDF

Key numbers

  • -2.6 per dayChange in daily moderate-to-severe hot flashes vs placebo at week 12 for fezolinetant 45 mg, trial 1Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 2.3%Share of women on fezolinetant 45 mg with liver enzymes over 3 times normal in pooled trialsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 120 mgUsual elinzanetant (Lynkuet) dose, taken once daily at bedtimeSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

At a glance

  • Fezolinetant (Veozah) / NK3 receptor antagonist, approved May 12, 2023; boxed warning for liver injury
  • Elinzanetant (Lynkuet) / dual NK1/NK3 antagonist, approved October 24, 2025; 120 mg at bedtime
  • Brisdelle (paroxetine 7.5 mg) / SSRI approved for hot flashes in 2013; a lower dose than used for depression
  • Hormone therapy labels / FDA requested boxed-warning changes in November 2025; first six products approved February 2026
  • STRAW+10 / the standard staging system, based on bleeding criteria
  • REPLENISH / single estradiol-progesterone capsule; no endometrial hyperplasia found at 12 months
  • SWAN / 3,302 women; median duration of frequent hot flashes 7.4 years
  • Estetrol (E4) / fetal estrogen; a 2008 review names hot flashes as a possible future use

What are the newest approved drugs for hot flashes?

Fezolinetant (Veozah) was approved on May 12, 2023, and elinzanetant (Lynkuet) on October 24, 2025; paroxetine 7.5 mg (Brisdelle) was approved for the same use back in 2013 [1][2][3]. Fezolinetant and elinzanetant both act on the neurokinin 3 (NK3) receptor; elinzanetant also blocks NK1 [2][3]. Neither is a hormone. Fezolinetant works by blocking NK3 receptor activity, which plays a role in the brain's control of body temperature [8]. Brisdelle is an SSRI at a dose lower than that used for depression and is not approved for any psychiatric condition [1].

How well does fezolinetant work, and what does it require?

SKYLIGHT 1 was a 12-week randomized, double-blind, placebo-controlled phase 3 study with a 40-week extension, run at 97 facilities, in women aged 40 to 65 with an average of seven or more moderate-to-severe hot flashes a day [4]. By the Veozah label, at week 12 the change in daily moderate-to-severe hot flash frequency versus placebo for the 45 mg dose was -2.6 per day in trial 1 (95% CI, -3.4 to -1.7), which compared 174 with 175 women, and -2.5 per day in trial 2 (95% CI, -3.6 to -1.5), which compared 167 with 167 women [2].

Safety is the part that shapes who can take it. The label carries a boxed warning for liver injury, added in December 2024 after a postmarketing report of liver injury about 40 days into treatment [8]. In pooled trials, transaminases above 3 times the upper limit of normal occurred in 2.3% of women on fezolinetant 45 mg (25 of 1,100) versus 0.9% on placebo (8 of 952) [2]. The label requires liver tests before starting and monthly for the first 3 months, then at 6 and 9 months, and says not to start if ALT or AST is 2 times the upper limit of normal or more, or total bilirubin is 2 times the upper limit or more [2]. It is contraindicated in women with cirrhosis, severe renal impairment or end-stage renal disease, and with CYP1A2 inhibitors [2].

How does elinzanetant differ?

Elinzanetant is taken as 120 mg (two 60 mg capsules) once daily at bedtime, with liver tests before starting and a follow-up at 3 months; pregnancy must be excluded first [3]. Pregnancy is still possible during perimenopause [9]. The label contraindicates elinzanetant in pregnancy and advises contraception during treatment and for 2 weeks after stopping [3].

In the two 12-week OASIS trials, postmenopausal women aged 40 to 65 with moderate-to-severe hot flashes were randomized to elinzanetant (199 and 200 women) or placebo (197 and 200 women), mean age 54.6 [5]. At week 12, elinzanetant reduced moderate-to-severe vasomotor symptoms versus placebo by 3.22 per 24 hours in OASIS 1 (95% CI, -4.81 to -1.63) and 3.24 per 24 hours in OASIS 2 (95% CI, -4.60 to -1.88) [5].

Elinzanetant has no boxed warning, but its label lists nervous-system effects (somnolence, fatigue, vertigo, dizziness, presyncope) in 11.9% on elinzanetant versus 3.5% on placebo across the three OASIS trials, a transaminase rise of 3 times the upper limit of normal or more in 0.6% versus 0.4%, and reports of seizure, including after marketing [3]. In the 52-week OASIS 3 trial, headache occurred in 9.6% versus 7.0%, fatigue in 7.3% versus 2.9% and dizziness in 6.1% versus 1.9% [3]. The label says to avoid strong CYP3A4 inhibitors and grapefruit, to reduce the dose to 60 mg with moderate CYP3A4 inhibitors, and to avoid strong and moderate CYP3A4 inducers [3].

Did the FDA change the hormone therapy warnings?

In stages, and not everywhere yet. On November 10, 2025, FDA asked manufacturers to remove the cardiovascular disease, breast cancer and probable dementia statements from the boxed warning and to keep the endometrial cancer boxed warning for systemic estrogen-alone products. For systemic products, FDA also asked to retain the cardiovascular and breast cancer warnings in the Warnings and Precautions section and to add WHI data for women aged 50 to 59 [6][10]. On February 12, 2026, FDA approved revised labels for six products spanning four categories, and said 29 companies had submitted proposed changes [7].

Label status still varies by product: the Premarin oral label effective June 4, 2026, still carries a box naming endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia, while the Divigel label effective February 27, 2026, has a box limited to endometrial cancer with unopposed estrogen [11][12].

The Menopause Society's 2022 position statement, which predates the label changes, states that hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and prevents bone loss and fracture; for women under 60 or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favorable, and longer durations are acceptable for documented indications such as persistent symptoms with periodic reevaluation [13].

What has the SWAN cohort shown?

SWAN enrolled 3,302 women at seven US sites, starting in 1996 [14]. Median total duration of frequent hot flashes and night sweats was 7.4 years, with median persistence of 4.5 years after the final menstrual period; women who first reported frequent symptoms while premenopausal or early perimenopausal had a median total duration over 11.8 years, and Black women had the longest total duration, a median of 10.1 years [14].

Body composition changed on a different timetable than weight. At the start of the transition, the rate of fat gain doubled and lean mass declined, continuing until about 2 years after the final period, while weight climbed steadily beforehand with no acceleration at the transition and flattened afterward [15].

Bone loss began 1 year before the final period and slowed but did not stop 2 years after it [16]. Over 10 years, cumulative lumbar spine loss was 10.6%, of which 7.38% occurred from 1 year before to 2 years after the final period; femoral neck loss was 9.1%, of which 5.8% occurred in that window [16].

Mood research comes from a separate population-based cohort followed for 8 years, where women with no history of depression were more than 4 times as likely to have high depression scores during the transition as before it (odds ratio 4.29), and 2.5 times as likely to receive a depressive disorder diagnosis (odds ratio 2.50) [17].

Is AMH a menopause test now?

No. AMH, antral follicle count, and inhibin B can support staging, but they are not standalone menopause tests because the assays are not standardized. Blood hormone tests are not usually needed to identify perimenopause [18][9]. The STRAW+10 consensus, which remains the standard staging system, defines early transition by cycle variability of 7 or more days recurring within 10 cycles and late transition by 60 days or more without a period, and applies a quantitative FSH criterion only in late transition, where a random FSH above 25 IU/L suggests it [18].

What people on Reddit report

These accounts come from people asking for credible research on early perimenopause, and from readers discussing how to take that evidence to a doctor and how a new study on menopause changes was received.

newpony · Perimenopause

There been a recent study about women with ADHD being more than likely to go through perimenopause up to 10 years earlier than neurotypical women.

Points to a recent study linking ADHD with earlier perimenopause and shares a link to it.

Read the source discussion

EROM4LIFE · Perimenopause

Yes. Google early perimenopause pubmed and you'll see a bunch of peer reviewed articles. Pubmed is a great resource and it's free to read the articles.

Says peer-reviewed articles on early perimenopause are free to find through PubMed.

Read the source discussion

moxvoxfox · Perimenopause

If they aren't free, one can email an author for a copy and they're often happy to share.

Advises that paywalled studies can be requested directly from their authors.

Read the source discussion

Comfortable-Law-7147 · Perimenopause

It's clear your doctor doesn't have any menopause training and can't be bothered to do her own basic research so rather than argue with her, find another doctor.

Argues that a doctor who dismisses early symptoms should be replaced, rather than argued with.

Read the source discussion

winterjinx · TwoXChromosomes

We already know that young girls are starting their cycles much earlier than they previously were so it stands to reason we are hitting perimenopause earlier too.

Reasons that earlier first periods suggest earlier perimenopause, and reports being told they are too young despite no other explanation.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

What about the genetics of menopause timing?

A 2021 study identified 290 genetic variants associated with age at natural menopause in about 200,000 women of European ancestry, with the implicated genes concentrated in DNA damage response pathways; women in the top 1% of genetic susceptibility had a risk of premature ovarian insufficiency comparable to carriers of FMR1 premutations [19]. The study is about the biology of ovarian ageing and its possible therapeutic targets, not a test for an individual woman's timeline [19].

What happened with the single estradiol-progesterone capsule?

The REPLENISH trial tested a single oral capsule combining 17-beta-estradiol and progesterone: a phase 3, 12-month, randomized, double-blind, placebo-controlled, multicenter study that enrolled 1,845 women between August 2013 and October 2015, of whom 1,835 received medication, 1,255 were in the endometrial safety population and 726 in the hot-flash substudy, mean age 55 [20]. No endometrial hyperplasia was found [20]. At week 12, the 1 mg estradiol/100 mg progesterone dose reduced hot flash frequency by 55.1 from baseline versus 40.2 with placebo, and severity by 1.12 versus 0.56 [20].

What about estetrol?

Estetrol (E4) is a natural estrogen made by the human fetus. A 2008 review describes it as orally bioavailable and, in rat tissue, estrogenic everywhere tested except breast tumor tissue, where it acted as an estrogen antagonist in the presence of estradiol, and names hot flashes and vaginal atrophy as possible future applications [21]. That is a drug profile and a list of potential uses, not an established menopause treatment.

Which non-hormonal options have guideline support?

The Menopause Society's 2023 nonhormone position statement recommends cognitive-behavioral therapy, clinical hypnosis, SSRIs/SNRIs, gabapentin and fezolinetant at the strongest evidence level, oxybutynin at the next level, and weight loss and stellate ganglion block at lower levels; it does not recommend paced respiration or supplements and herbal remedies, and it notes that hormone therapy remains the most effective treatment for vasomotor symptoms [22].

Paroxetine is the only SSRI with an FDA-approved product for this use: Brisdelle, paroxetine mesylate 7.5 mg once daily at bedtime, a dose lower than the doses used for depression [1]. Two randomized trials totaling 591 women on paroxetine 7.5 mg and 593 on placebo met all primary endpoints in the 24-week study and three of four in the 12-week study [23]. The label warns that paroxetine is a strong CYP2D6 inhibitor that lowers levels of tamoxifen's active metabolite and says to consider avoiding the combination [1].

Does the gut microbiome affect menopause symptoms?

This is where the research is earliest. One review explains the estrobolome concept: gut bacteria secrete beta-glucuronidase, which deconjugates estrogens into active forms, and lower microbial diversity may reduce circulating estrogen [24]. A 2025 review says declining estrogen appears to influence the microbiota and that prebiotics and probiotics such as Lactobacillus have increased bacterial diversity and improved metabolic measures in menopausal women, while stating that evidence on the underlying mechanisms remains limited [25]. A 2026 review adds that hormonal shifts affect both vaginal and gut microbiomes and points to diet as a possible modulator [26].

Frequently asked questions

What is the newest non-hormonal drug for hot flashes?
Elinzanetant (Lynkuet) was approved on October 24, 2025. It is a dual NK1 and NK3 receptor antagonist taken as 120 mg (two 60 mg capsules) once daily at bedtime, with liver tests at baseline and at 3 months, and it is contraindicated in pregnancy [3]. Fezolinetant (Veozah) was approved in 2023 and Brisdelle (paroxetine 7.5 mg) in 2013 [2][1].
How much do the NK3 drugs reduce hot flashes?
By the Veozah label, fezolinetant 45 mg reduced daily moderate-to-severe hot flashes by 2.6 more per day than placebo at week 12 in trial 1 and 2.5 more in trial 2 [2]. Elinzanetant 120 mg reduced them by 3.22 and 3.24 more per 24 hours than placebo in OASIS 1 and OASIS 2 [5].
Did the FDA remove the hormone therapy boxed warnings?
Partly. FDA requested removal of the cardiovascular, breast cancer and probable dementia statements from the boxed warning in November 2025 and approved revised labels for six products on February 12, 2026 [6][7]. The endometrial cancer warning stays on systemic estrogen-alone products, and many labels, including Premarin, still carry the older box [10][11].
How long does perimenopause last?
About 4 years on average, but it can last up to 10 years, and it usually begins in a woman's 40s [27][9]. Pregnancy is still possible during perimenopause [27][9].
What did the REPLENISH trial show?
The single estradiol-progesterone capsule was tested in 1,845 women over 12 months, and no endometrial hyperplasia was found [20]. At week 12 the 1 mg estradiol/100 mg progesterone dose reduced hot flash frequency by 55.1 from baseline versus 40.2 with placebo [20].
Is gut bacteria research ready to treat menopause symptoms?
Reviews describe the estrobolome as a route by which gut bacteria affect estrogen levels; a 2025 review reports that prebiotics and probiotics such as Lactobacillus increased bacterial diversity and improved metabolic measures in menopausal women, while stating that evidence on mechanisms remains limited [24][25].

References

Show all 29 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Brisdelle paroxetine 7.5 mg prescribing information. Brisdelle paroxetine 7.5 mg label
  2. U.S. National Library of Medicine, DailyMed. Veozah fezolinetant prescribing information. Veozah fezolinetant label
  3. U.S. National Library of Medicine, DailyMed. Lynkuet elinzanetant prescribing information. Lynkuet elinzanetant label
  4. Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102.
  5. Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024;332(16):1343-54.
  6. U.S. Food and Drug Administration.
  7. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products | FDA.
  8. FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause. Stop Medicine if Signs and Symptoms of Liver Injury Occur - Drug Safety Communication | FDA.
  9. Menopause basics | Office on Women's Health.
  10. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy | FDA.
  11. U.S. National Library of Medicine, DailyMed. Premarin oral tablets (still older boxed warning) (estrogens, conjugated) prescribing information. Premarin oral tablets (still older boxed warning) (estrogens, conjugated) label
  12. U.S. National Library of Medicine, DailyMed. Divigel estradiol gel (revised boxed warning) prescribing information. Divigel estradiol gel (revised boxed warning) label
  13. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
  14. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-9.
  15. Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5).
  16. Greendale GA, Sowers M, Han W, Huang MH, Finkelstein JS, Crandall CJ, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). J Bone Miner Res. 2012;27(1):111-8.
  17. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63(4):375-82.
  18. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging - PMC.
  19. Ruth KS, Day FR, Hussain J, Martínez-Marchal A, Aiken CE, Azad A, et al. Genetic insights into biological mechanisms governing human ovarian ageing. Nature. 2021;596(7872):393-397.
  20. Lobo RA, Archer DF, Kagan R, Kaunitz AM, Constantine GD, Pickar JH, et al. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial. Obstet Gynecol. 2018;132(1):161-170.
  21. Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47-58.
  22. New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
  23. Simon JA, Portman DJ, Kaunitz AM, Mekonnen H, Kazempour K, Bhaskar S, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20(10):1027-35.
  24. Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017;103:45-53.
  25. Liaquat M, Minihane AM, Vauzour D, Pontifex MG. The gut microbiota in menopause: Is there a role for prebiotic and probiotic solutions?. Post Reprod Health. 2025;31(2):105-114.
  26. Ferrando ML, Busonero F, Crobu F, Sanna S. Aging in women - The microbiome perspective. Ageing Res Rev. 2026;113:102950.
  27. Menopause | Menopause Symptoms | MedlinePlus.
  28. Reddit participants. Any research that proves early onset peri/menopause? (r/Perimenopause). Accessed 2026-11-10.
  29. Reddit participants. Menopause May Change Almost Every System in the Body, Study of 300 Million Lab Tests Suggests (r/TwoXChromosomes). Accessed 2026-11-10.
Evidence overview for Perimenopause Emerging Research and Trials to Watch